Cision PR Newswire
NEO LAWSUIT ALERT: Levi & Korsinsky Notifies NeoGenomics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
News provided byLevi & Korsinsky, LLP
Jan 26, 2023, 5:45 AM ET
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NeoGenomics investors who were adversely affected by alleged securities fraud between February 27, 2020 and April 26, 2022. Follow the link below to get more information and be contacted by a member of our team:
NEO investors may also contact Joseph E. Levi, Esq. via email at firstname.lastname@example.org or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."
WHAT'S NEXT? If you suffered a loss in NeoGenomics during the relevant time frame, you have until February 6, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neo-lawsuit-alert-levi--korsinsky-notifies-neogenomics-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-301731185.html
SOURCE Levi & Korsinsky, LLP